

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 2, 2023**

**YIELD10 BIOSCIENCE, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-33133**  
(Commission File Number)

**04-3158289**  
(IRS Employer Identification No.)

**19 Presidential Way,  
Woburn, Massachusetts**  
(Address of principal executive offices)

**01801**  
(Zip Code)

Registrant's Telephone Number, Including Area Code: **(617) 583-1700**

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common stock, par value \$0.01 per share	YTEN	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

Attached hereto as Exhibit 99.1 and incorporated herein by reference is an updated corporate presentation of Yield10 Bioscience, Inc.

**Item 9.01. Financial Statements and Exhibits**

(d)

**Exhibits**

**Exhibit  
No.**

**Description**

---

<a href="#">99.1</a>	<a href="#">Investor Presentation</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

YIELD10 BIOSCIENCE, INC.

Date: August 2, 2023

By: /s/ Oliver P. Peoples  
Oliver P. Peoples  
President & Chief Executive Officer

---



**Yield10 Bioscience, Inc.**

NasdaqCM: YTEN

**Investor Presentation**

**August 2023**

*Sustainable Growth Starts with a Seed*



*The statements made by Yield10 Bioscience, Inc. (the "Company," "we," "our" or "us") herein regarding the Company and its business may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe the Company's future plans, projections, strategies and expectations, including statements regarding future results of operations and financial position, business strategy, prospective products and technologies, expectations related to research and development activities, timing for receiving and reporting results of field tests and likelihood of success, and objectives of the Company for the future, and are based on certain assumptions and involve a number of risks and uncertainties, many of which are beyond the control of the Company, including, but not limited to, the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and other reports filed by the Company with the Securities and Exchange Commission (the "SEC"). Forward-looking statements include all statements which are not historical facts and can generally be identified by terms such as anticipates, believes, could, estimates, intends, may, plans, projects, should, will, would, or the negative of those terms and similar expressions.*

*Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and may be beyond the Company's control, you should not rely on these statements as predictions of future events. Actual results could differ materially from those projected due to our history of losses, lack of market acceptance of our products and technologies, the complexity of technology development and relevant regulatory processes, market competition, changes in the local and national economies, and various other factors. All forward-looking statements contained herein speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements, whether to reflect new information, events or circumstances after the date hereof or otherwise, except as may be required by law.*

*We have filed a registration statement on Form S-1 (File No. 333-273240), including a preliminary prospectus, dated August 1, 2023, with the Securities and Exchange Commission ("SEC") for the offering to which this communication relates. The registration statement has not yet become effective. Before you invest, you should read the registration statement, the preliminary prospectus and the final prospectus (when available) for more complete information about us and this offering. You may also retrieve copies of these documents for free on the SEC's website at <https://www.sec.gov>. Alternatively, copies of the preliminary prospectus and the final prospectus, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, Attention: Syndicate Department, or via email at [syndicate@maximgrp.com](mailto:syndicate@maximgrp.com) or telephone at (212) 895-3745, or from Lake Street Capital Markets, LLC, Attention: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, Minnesota 55402, or by emailing [syndicate@lakestreetcm.com](mailto:syndicate@lakestreetcm.com) or by calling (612) 326-1305.*

# Company Overview

## Yield10 at a Glance

Ticker:	YTEN
Exchange:	NasdaqCM
Stock Price <sup>(1)</sup> :	\$2.27
Fully Diluted ("FD") Shares Outstanding <sup>(2)</sup> :	7.4M
FD Market Capitalization <sup>(1,2)</sup> :	\$16.7M
Enterprise Value <sup>(3)</sup> :	\$12.2M
Q1 2023 / FY 2022 Revenue:	\$60k / \$450k
Cash as of June 30, 2023 <sup>(4)</sup> :	\$2.3M

## About Yield10

- Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies designed to enable step-change increases in crop yield in the United States and Canada
- The Company is developing superior Camelina varieties to produce PHA bioplastics, low-carbon index feedstocks for renewable diesel biofuel, and land-based Omega-3 DHA and EPA oils
- Yield10 uses its Trait Factory platform to increase photosynthesis in crops and extract more carbon (CO<sub>2</sub>) from the air

1. As of the close on August 1<sup>st</sup>, 2023

2. Based on 5,078,557 shares outstanding as of March 31, 2023 and includes the following: (i) 1,160,114 shares of common stock issuable upon exercise of the company's options outstanding as of March 31, 2023 at a weighted average exercise price of \$12.29 per share; (ii) 14,270 shares of common stock issuable upon exercise of warrants outstanding as of March 31, 2023 at an exercise price of \$201.60 per share; (iii) 1,114,278 shares of common stock issuable upon exercise of Series B Warrants at an exercise price of \$8.00 per share; and (iv) 750 shares of common stock issuable upon exercise of immediately vested warrants outstanding at an exercise price of \$116.00 per share.

3. Calculated using balance sheet data as of March 31, 2023, stock price as of the close on August 1<sup>st</sup>, 2023, and based on 5,078,557 shares outstanding as of March 31, 2023

4. As of June 30, 2023, we had cash and cash equivalents of approximately \$2.3 million. Cash and cash equivalents as of June 30, 2023 is preliminary, unaudited and subject to completion and may differ from what will be reflected in our unaudited interim financial statements as of and for the three and six months ended June 30, 2023. Our unaudited interim condensed financial statements as of and for the three and six months ended June 30, 2023 will not be available to you prior to investing in the securities offered by the prospectus.

# Yield10 Investment Highlights

## An Agricultural Bioscience Company

### LEADERSHIP

- Strong leadership and R&D team  
(Boston, USA and Saskatoon, Canada)
- Experienced Board of Directors

### COMMERCIAL VISION

Plans to Scale Camelina to 30 million acres

- Camelina grain contracting
- Revenue from seed product offtake agreements



## Focused on the Oilseed Camelina

### MARKET FOCUS

- BIOFUEL FEEDSTOCK OIL
  - Next – Omega-3 oils
  - Future – PHA Bioplastics

### TECHNOLOGY FOCUS

Goals to Increase revenue and margins

- Increase production acres
- Increased harvest value
- Next - higher value omega-3 oil

### EXECUTION FOCUS

- Grower contracts
- Grain/oil Offtake Agreements
- Technology and regulatory approvals



# Recent Yield10 Business Accomplishments

## Building Commercial Momentum

- Establishing the supply chain

Value Chain	Seed Production	Grower Contracts	Grain/Oil Offtake	Crush/refining
Status	✓	✓	✓	underway

- First value chain partnership in place (private Crusher/Biorefiner) ✓
- First commercial winter production harvested and delivered to partner ✓
- Spring grower contracting completed under grain offtake agreements ✓
- Grower outreach is underway for winter Camelina contracting in fall of 2023
- Expecting first product revenue in second half of 2023**

Camelina Grain Harvest - Alberta, July 2023



- Progressing additional value chain prospects




- Marathon Petroleum Corporation:** non-binding Letter of Intent (“LOI”) for investment and partnership for Camelina in biofuel (regional exclusivity until August 25<sup>th</sup>)
- Mitsubishi Corporation:** Memorandum of Understanding (“MOU”) for SAF
- American:** MOU for collaboration to develop value chain for Camelina in SAF




Camelina Grain Delivered - Alberta, July 2023



## Map of Biofuels Facilities<sup>1</sup>



- 6 billion gallons of new capacity for funded RD projects in the US<sup>1</sup>



1. 10 new biofuels facilities in US/Canada announced in last ~9 months. RD capacity image credit - FastMarkets.
2. Image credit: Montana Renewables Investor Presentation.
3. [https://apple.news/Ab2GQvF10T5S4ZT2-DN\\_rQ](https://apple.news/Ab2GQvF10T5S4ZT2-DN_rQ)
4. <https://www.argusmedia.com/en/news/2453500-japan-to-implement-policies-to-raise-saf-use-supply>

## Sustainable Aviation Fuel (SAF)

**EU agrees to decarbonize air travel with the 'world's largest green fuels mandate for aviation'**

**Japan to implement policies to raise SAF use, supply**

PUBLISHED: 05:00 AM GMT+01:00 ON 2023-05-09 09:02:07

Published Date: 28 May 2023

Japan's trade and industry ministry (METI) plans to introduce a sustainable aviation fuel (SAF) mandate to achieve the country's target of 10% SAF use by 2030, as well as tax exemptions.

Region	2030 SAF Target (gal/yr)
US	3 billion
EU	462,000,000
Japan	453,000,000

- There are still major long-term risks for biofuels producers
  - Secure feedstock oil supply
  - Food vs Fuel – Loss of biofuel incentives for food oils?

**Estimated opportunity for ~44 million acres of oilseed cover crops in the US and Canada**

**>\$12 billion feedstock oil**  
 (@ 1400lb/acre, 40% oil and \$0.50/lb oil)

# Yield10 Platform Crop - Camelina


## Yield10 Vision: Transition Camelina from a niche crop to > 30 million acres

- Promising oilseed crop
  - Uses same farming, storage and processing assets as other oilseed e.g. canola
  - Seed oil levels ~ 40% of seed weight, protein meal ~55% of seed weight
- Both spring and winter varieties
  - Winter varieties, potential use as cover crop for corn and soybean acres
  - We believe Yield10 leads in input and performance traits
- Promising platform crop for novel high value seed products

### June 2023, Camelina Crop Insurance<sup>1</sup>

#### USDA Helps Agricultural Producers Meet Demand for Camelina

SPOKANE, Wash., June 30, 2023 – The U.S. Department of Agriculture (USDA) announced today that it will expand insurance for camelina in direct response to the anticipated increase in demand for the crop for biofuel production.



Greenhouse grown Camelina



Camelina field plots at flowering



Commercial scale winter Camelina growth

<sup>1</sup> <https://biodieselmagazine.com/articles/2518791/usda-expands-crop-insurance-for-camelina>

# Establishing Commercial Production

Plans to transition Camelina from a niche crop to major crop on > 30 million acres

- **Establish production AND the value chain**
  - Advanced varieties – cold tolerant, early maturing
  - Partnering with growers
  - Offtake Agreements for grain/oil
    - Minimize working capital for grain inventory
- **Increase revenue and margins - technology**
  - **Accelerate grower adoption**
    - **Herbicide package to fit crop rotations**
      - Weed control + tolerance to soil herbicide residues
    - **Winter cover crop**
      - New crop rotation options, additional grower revenue, soil health/carbon, reduced nutrient runoff
  - **Increase harvest value**
    - Lower CI (carbon intensity) oil from winter cropping– higher value feedstock oil
    - Seed yield and seed oil content, future higher value seed products (omega-3 oil)
    - Improved protein meal value - **Food and fuel**




1. CI reduction is based on Yield10's internal estimates of carbon savings versus the production of either petroleum plastics or bioplastics from bio-fermentation. See Yield10's white paper "Biofuels and Bioplastics Commercial Development Plan" for additional details.

# Establishing Production - Early Camelina Varieties

Value-advantaged spring and winter Camelina available under grower contract

**E3902 (Spring Gene-Edited)**




E3902 is a triple gene-edited spring Camelina

**WDH2 (Winter Cold Tolerant)**



Cold hardy winter Camelina variety

**WDH3 (Winter Short Cycle)**



Early maturing winter Camelina variety



# Establishing Production – Grain Production and Offtake

- Winter Camelina planted in the Fall of 2022
- **Established the value chain** by partnering with private crusher/biorefiner ✓



Winter Camelina June 2023



Winter Camelina Grain Harvest – July 2023



Camelina Grain Delivered to Biofuel Facility  
July 2023


- Spring 2023 grower contracting completed Q2 ✓
- Winter 2023/2024 grower contracts to be completed Q3



## Plans to transition Camelina from a niche crop to major crop on > 30 million acres

- **Establish production**
  - Advanced varieties – cold tolerant, early maturing
  - Partnering with growers
- **Increasing revenue and margins - Technology**
  - **Accelerate grower adoption – increase production acres**
    - **Herbicide package to fit crop rotations**
      - Weed control + tolerance to soil herbicide residues
    - **Winter cover crop**
      - New crop rotation options, increase grower revenue, soil health/carbon, reduced nutrient runoff
  - **Increase harvest value**
    - Lower CI (carbon intensity) oil from winter cropping– higher value feedstock oil
    - Seed yield and seed oil content – future higher value seed products (omega-3 oil)
    - Improved protein meal value - **Food and fuel**
- **Own or Control 21 Patent Applications pending** (HT, seed yield, seed oil etc.)

HT Camelina May Accelerate Grower Adoption ?




1. CI reduction is based on Yield10's internal estimates of carbon savings versus the production of either petroleum plastics or bioplastics from bio-fermentation See Yield10's white paper "Biofuels and Bioplastics Commercial Development Plan" for additional details.

# Progress on Herbicide Trait for Robust Weed Control

## Plans to increase revenue and margins

- Provide state of the art broadleaf weed control for growers
  - Increase yield by reducing weed pressure
  - Enable growers to leverage HT Camelina to manage their entire crop rotations


### Anticipated Timeline and Milestones for HT Camelina Development



# Goal: Stacked Herbicide Trait for Robust Weed Control

## Plans to increase revenue and margins

- Combine over-the-top broadleaf herbicide tolerance with soil residual tolerance (“Stacked HT”)
  - Enable growers to use land previously treated with Group 2 herbicides
  - Expand acreage available for growing Camelina
- Increase ease of use and profitability for growers
- Increase revenue by increasing production acres and yield




*Note: Development path for spring E3902 Camelina germplasm with stacked HT trait*



# Biofuels Competitive Landscape

## Yield10 plans to retain control of its future while partnering for biofuels


- Partnerships are being formed across the value chain
- Majority of new oilseed innovators are now controlled by Ag or oil majors

Company	Ownership	Oilseed	Crush Partner	Refinery Partner	Offtake
NuSEED	Subsidiary of NuFarm (Australia)	Carinata		British Petroleum	British Petroleum
CoverCress	Majority owned by Bayer	Pennycress	BUNGE	REG/Chevron	REG/Chevron <sup>1</sup>
Sustainable Oils	Owned by GCEH	Camelina (Spring)	JG Boswell	Global Clean Energy	Global Clean Energy
Vision BioEnergy	S&W Seed (minority) Shell (majority)	Camelina		SHELL	SHELL
Corteva	Public Co.	Canola	BUNGE	REG/CHEVRON	REG/CHEVRON
	Public Co.	Camelina (Spring/ Winter)	Confidential		Negotiating offtake agreements

Note 1, The acquisition of REG by Chevron is ongoing.

# Yield10 - Omega-3 Oil Opportunity

Tailwinds for sustainable, scalable sources of omega-3 oils



1. <https://www.intrafish.com/fisheries/peru-cancels-all-important-first-anchovy-fishing-season/2-1-1464552>
2. <https://www.seafoodsource.com/news/supply-trade/global-fishmeal-production-up-30-percent-in-2023-iff-finds#:~:text=%E2%80%9CThis%20announcement%20is%20of%20strategic,fishmeal%20and%20fish%20oil%20production%E2%80%9D>
3. <https://www.seafoodsource.com/news/aquaculture/aquaterra-s-omega-3-oil-gets-norwegian-approval-for-use-in-aquafeed>
4. [How Sustainable Farming On Land And Sea Can Work Together To Meet Our Growing Need For Protein](https://www.forbes.com/business/food-drink/2023/07/12/sustainable-farming-land-sea-protein/)


# Yield10 - Omega-3 Oil Opportunity - Status

## EPA and DHA Omega-3 oils are essential for human health and wellness


- Fish oil is the primary source of EPA and DHA Omega-3s in the human diet
- Minimum levels of EPA and DHA are required in salmon diets for health and productivity
  - EPA8 Camelina line – up to 29% EPA in oil, target pharma/nutraceutical markets
  - DHA1 Camelina line - ~ 10%EPA + 10% DHA, drop in fish oil replacement
- Yield10 believes it can leverage the operating foundation established for biofuels


Yield10's Camelina Omega-3 vs Fish Oil and Competitors

Comparison Point	Fish Oil	Yield10's Camelina Omega-3	Competitors' Canola Omega-3	Competitors' Algae Omega-3
Cost	\$\$	\$ Vegetable Oil Costs	\$ Vegetable Oil Costs	\$\$\$\$ ~3-4x more expensive
EPA/DHA Levels <sup>4</sup>	✓	✓ ~9% EPA, 11% DHA	✗ EPA or DHA	✓
Ability to Meet Demand	✗ Overfishing	✓ Crops are Scalable	✓ Crops are Scalable	✗ High CapEx
Sustainability	✗ Overfishing	✓	✓	✗ Higher CO2 Emissions
Crop Segregation Risks	✓	✓ Not a Food Crop	✗ Significant Risks	✓


→

>>>> 2016-2021 UK, Canada, US	2017-2020 Published Studies	Q4, 2020 -2022	2023 - >>>>>
Multi year, multi acre field tests  <div style="text-align: right; color: green; font-weight: bold;">✓</div>	Product validation in aquafeed & human trials "Camelina DHA 1 oil effectively replaces fish oil"  <div style="text-align: right; color: green; font-weight: bold;">✓</div>	<ul style="list-style-type: none"> <li>Yield10 secures commercial rights</li> <li>Funds RRES R&amp;D program</li> <li>Assists with patent prosecution</li> </ul> <div style="text-align: right; color: green; font-weight: bold;">✓</div>	<ul style="list-style-type: none"> <li>July 2023, Yield10 files RSR for regulatory approval of EPA 8 line with USDA-APHIS</li> <li>EPA8 line planted at acre-scale to produce planting seed and oil samples</li> <li>RSR for DHA 1 Camelina line in preparation</li> <li>Planning scale up of EPA8 and DHA1 Camelina lines</li> <li>Developing detailed business plan to enable commercial launch</li> <li>Timeline for anticipated commercial launch in development</li> </ul> <div style="text-align: right; color: green; font-weight: bold; font-size: 1.5em;">✓</div>




16

1. <https://academic.oup.com/ajcn/article/114/4/1447/6301120>

## Investment ongoing to achieve key strategic objectives

Operating Results	Q1 2023	Q1 2022
Revenue	\$0.1 million	\$ 0.1 million
R&D Expense	\$ 2.2 million	\$ 1.8 million
G&A Expense	\$ 1.7 million	\$ 1.7 million
Net Loss	\$ 3.8 million	\$ 3.3 million

### Balance Sheet

- **\$2.3 M in cash and cash equivalents at the end of second quarter<sup>2</sup>**
- \$1.8 M in cash and cash equivalents at the end of first quarter
- \$1.0 M Convertible Note associated with LOI with Marathon Petroleum signed on April 28
- \$2.7 M net proceeds in a Registered Direct offering completed on May 5
- Net operating cash usage of \$2.7 M for the first quarter of 2023
- Expect to book product revenue from harvest of Camelina grain in Q4-2023

<sup>1</sup> Current as of date of conference call on May 10, 2023.

<sup>2</sup> As of June 30, 2023, we had cash and cash equivalents of approximately \$2.3 million. Cash and cash equivalents as of June 30, 2023 is preliminary, unaudited and subject to completion and may differ from what will be reflected in our unaudited interim financial statements as of and for the three and six months ended June 30, 2023. Our unaudited interim condensed financial statements as of and for the three and six months ended June 30, 2023 will not be available to you prior to investing in the securities offered by the prospectus.

# On Track to Achieve Key Milestones in 2023 and Beyond

Corporate, Commercial and R&D Milestones	Period
<b>Expand commercial activities targeting the Biofuel market</b> <ul style="list-style-type: none"> <li>- <b>Generate first product revenue in 2023 from fall 2022/spring 2023 grower contracts</b></li> <li>- <b>Advance partnership discussions with Mitsubishi and Marathon Petroleum</b></li> <li>- <b>Obtain regulatory clearance for herbicide tolerant Camelina</b></li> <li>- Form additional partnerships and/or sign offtake agreement(s) across the biofuel value chain</li> </ul>	<b>2023</b> <i>Ongoing</i> <i>Ongoing</i> <i>Ongoing</i> <i>Ongoing</i>
<b>Execute on grower engagement program ensuring rapid offtake of Camelina grain; engage growers in 2023 production contract program, hold field events and build visibility for the benefits of growing Camelina</b> <ul style="list-style-type: none"> <li>- <b>Expand grower contracts for winter Camelina and offtake of grain to crushers/refiner</b></li> <li>- Build seed inventory to ramp up contracted acres of spring and winter Camelina</li> </ul>	<b>2023</b> <i>Ongoing</i> <i>Ongoing</i>
<b>Continue to build industry leading, differentiated Camelina varieties</b> <ul style="list-style-type: none"> <li>- <b>Generate data and seed inventory to support launch of HT and stacked HT Camelina</b></li> <li>- Plant spring Camelina field trials, including HT, yield, and omega-3 traits</li> <li>- <b>Demonstrate stacked HT tolerant Camelina in field trials</b></li> </ul>	<b>2023</b> <i>Ongoing</i> <i>Completed in Q2</i> <i>Completed in Q3</i>
<b>Progress technology and commercial development activities, to address other key market opportunities</b> <ul style="list-style-type: none"> <li>- <b>File RSR for trait regulatory approval and complete business plan for launch of Omega-3 oils</b></li> <li>- Progress PHA bioplastic trait optimization</li> </ul>	<b>2023</b> <i>Ongoing</i> <i>Ongoing</i>
<b>Expand intellectual property portfolio</b>	<b>2023+</b>

# Yield10 Investment Highlights

## An Agricultural Bioscience Company

### LEADERSHIP

- Strong leadership and R&D team  
(Boston, USA and Saskatoon, Canada)
- Experienced Board of Directors

### COMMERCIAL VISION

Plans to Scale Camelina to 30 million acres

- Camelina grain contracting
- Revenue from seed product offtake agreements



## Focused on the Oilseed Camelina

### MARKET FOCUS

- BIOFUEL FEEDSTOCK OIL
  - Next – Omega-3 oils
  - Future – PHA Bioplastics

### TECHNOLOGY FOCUS

Goals to Increase revenue and margins

- Increase production acres
- Increased harvest value
- Next - higher value omega-3 oil

### EXECUTION FOCUS

- Grower contracts
- Grain/oil Offtake Agreements
- Technology and regulatory approvals



## Yield10 | BIOSCIENCE Leadership Team



**Oliver Peoples**  
President & CEO

- Co-founded Metabolix/Yield10
- 30+ years of technology innovation/commercial development
- PhD Molecular Biology, University of Aberdeen & research scientist in Department of Biology, MIT



**Kristi Snell**  
VP Research & CSO

- Led plant science research at Metabolix, co-founded Yield10
- PhD Organic Chemistry, Purdue University & Postdoc in Biochemistry and Metabolic Engineering, MIT



**Lynne Brum**  
VP Planning & Communications

- 25+ years experience in corporate communications and planning; former EVP Porter Novelli Life Sciences, VP Vertex Pharmaceuticals
- MBA, Simmons' School of Management



**Charles Haaser**  
VP Finance & CAO

- 30+ years experience in finance and accounting; Principal Accounting Officer and acting CFO at ABIOMED, Corporate Controller at Indevus Pharmaceuticals
- MBA, Northeastern & MS in Taxation, Bentley University



**Darren Greenfield**  
Senior Director, Seed Operations

- 25+ years experience in Canola seed operations
- Experience managing the development and commercial production of proprietary Canola plant varieties
- Experience with identity preserved supply chains for specialty products



## Yield10 | BIOSCIENCE Board of Directors



**Robert L. Van Nostrand**  
Director & Chairman

- Chairman since 2013 and a Director since 2006
- 30+ years in life sciences and finance
- 20 years at OSI Pharmaceuticals, most recently as SVP and CFO

(osi) pharmaceuticals



**Anthony J. Sinskey, ScD**  
Director

- Co-founded Metabolix/Yield10
- Professor of Biology at MIT
- Scientific co-founder of several other companies including Genzyme, Merrimack Pharmaceuticals and Tephra

MIT Massachusetts Institute of Technology  
genzyme  
MERRIMACK  
Metabolix



**Richard W. Hamilton, PhD**  
Director

- Director since 2017
- 30+ years in crop development
- 18 years at Ceres, Inc. serving in leadership positions including CEO, CFO and board member
- PhD in Molecular Biology at Vanderbilt University

ceres



**Sherri M. Brown, PhD**  
Director

- Director since 2020
- 28 years at Monsanto serving in leadership positions involving global commercialization of new products, including biotech traits for soybean, canola and corn
- PhD in Genetics, Molecular and Cellular Biology at Indiana University

MONSANTO



**Willie Loh,**  
Director

- Advisor to the board since June 2022
- 15 years at Cargill in VP/AVP roles including Market Development, Marketing, Oils, Sales
- Expertise in crushing and in contract growing of specialty oils through Cargill Canola

Cargill  
Helping the world thrive



**Oliver Peoples, PhD**  
President, Director & CEO

- Co-founded Metabolix/Yield10
- 30+ years of technology innovation/commercial development
- PhD Molecular Biology, University of Aberdeen & research scientist in Department of Biology, MIT

UNIVERSITY OF ABERDEEN  
MIT Massachusetts Institute of Technology  
Metabolix



# Portfolio of Camelina Traits in Development

Trait	Camelina Phenotype	Trait Source	Comments
HT 1	Tolerance to over-the-top herbicide	Known gene	YTEN patent pending on HT Camelina
HT 1 plus Group 2 HT	Tolerance to over-the-top herbicide plus Group 2 herbicide soil residues	Known gene	YTEN patent pending on HT Camelina
HT 1 plus HPPD HT	Tolerance to over-the-top and HPPD soil residues	Proprietary HPPD <sup>1</sup> trait	Recently added to portfolio Enable rotation in corn/soy
E3902	Increased seed oil (5%)	Yield10	PCT/US2020/043063
C3004	Increased vigor and seed yield	Yield10	PCT/US19/49281
C3007	Increased seed oil Increased seed yield	U. Missouri <sup>2</sup> Yield10	Issued US 10,883,113 PCT/US2021/045717
C3020	Increased seed oil	Yield10	PCT/US2020/032696
C3019, C3021, C3022	TBD-in testing	Yield10	PCT/US2020/032696
C3006	Increased seed yield and oil	Yield10	PCT/US2016/026767
C3026	TBD-in testing	Yield10	PCT/US2021/018743
Yield trait stack	Increased seed yield and oil	Yield10	Patent in preparation

<sup>1</sup> Exclusive option to novel HPPD trait

<sup>2</sup> Exclusive License from U. Missouri for use in increasing oil content in crops



**Yield10 Bioscience, Inc.**

NasdaqCM: YTEN

**Investor Presentation**

**August 2023**

*Sustainable Growth Starts with a Seed*

